| Compound | FOXO4-DRI |
|---|---|
| Category | Senolytic peptide |
| Class | Metabolic and Mitochondrial Compounds |
| Evidence tier | Preclinical |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
This entry covers FOXO4-DRI, a senolytic peptide, graded "Preclinical" in this catalog's evidence system. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
A cell-penetrating D-retro-inverso peptide designed to disrupt FOXO4-p53 binding and selectively clear senescent cells — the most-cited senolytic peptide in animal research.
Mechanism of Action
In senescent cells, FOXO4 tethers p53 and blocks apoptosis; the DRI variant displaces this interaction, allowing programmed cell death of senescent — but not healthy — cells.
Research and Evidence
The landmark mouse study (2016) reported improved renal function and physical performance in aged and fast-aging mice. No human trials of the peptide exist.
Safety and Side Effects
No human safety data; senescent-cell clearance in humans carries real physiological unknowns.
Frequently Asked Questions
What is the evidence tier of FOXO4-DRI?
FOXO4-DRI is graded "Preclinical" on this site. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
Is FOXO4-DRI an approved medicine?
No. Preclinical means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for FOXO4-DRI?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for FOXO4 senolytic studies (none registered). [source]
Evidence tier: Preclinical · Last reviewed: 2026-09-05 · Sources cited below.